We sincerely appreciate receiving comments that highlight critical concerns regarding our investigation. Below, we address the issues raised by the author.

First, the concern regarding the sufficiency of a one-year washout period is acknowledged. However, based on the pharmacokinetic profiles of the medications involved, this duration should be adequate. For calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEi), and angiotensin II receptor blockers (ARBs), the pharmacological effects are relatively short-lived. Short-acting CCBs typically have a duration of action of 4–8 h, while long-acting CCBs last 18–50 h [1]. For ACE inhibitors, short-acting formulations have a half-life of 1–2 h, and long-acting ones extend up to 12 h. Similarly, ARBs generally exhibit durations of action ranging from 11 to 15 h [2]. Thus, it is reasonable to assume that the pharmacological effects of these medications would have completely dissipated within the one-year washout period.